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ABSTRACT: Introduction and Aims: Combination antiretroviral therapy (cART) has 
improved morbidity and mortality in patients with HIV across countries including 
countries in sub-Sahara Africa. However, cART is associated with renal impairment. The 
lack of pre-cART data in a recently published study limited the discussion on renal-based 
treatment outcomes with cART, which could have important clinical implications. 
Consequently, the aim of this paper is to correct this. Methods: Longitudinal 
retrospective study, with renal function assessed pre-cART and at various time points on 
cART using the Cockcroft-*DXOW PHWKRG 7KH GDWD VRXUFH ZDV WKH SDWLHQWV¶ FDUH
booklets. Results: 71 patients were included. The majority were adults and female. 
Before cART initiation, 70.4% and 29.6% had abnormal and normal CrCl, respectively. 
CrCl was normalised in 24% of patients, while abnormal in the remainder. The mean 
(median) time to normalisation was 47.4 (33.7) months, observed more in paediatric than 
adult patients (p = 0.014). However, in paediatric patients, normalisation took longer than 
in adult patients. The reduction in CrCl, was observed at variable time points. 9/16 
patients experienced a decline during first-line cART and 7 of these were receiving TDF. 
7/16 experienced this during second-line cART and 6 were receiving TDF. Conclusion: 
HIV is typically the cause of renal impairment prior to cART, with TDF likely to be the 
cause of renal impairment during cART. Consequently, co-administration of TDF with 
other nephrotoxic drugs should be undertaken with caution if unavoidable. Overall, 
improvement in renal impairment was faster in adults. 
INTRODUCTION: Combination antiretroviral 
therapy (cART) has resulted in considerable 
improvements in both the quality and length of life 
of HIV infected patients, especially in sub-Sahara 
Africa, the region worst hit by the human immuno-
deficiency virus (HIV) 1, 2, 3. 
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HIV infection has been associated with HIV 
associated nephropathy (HIVAN), which is known 
to affect African patients, or patients of African 
descent, more than others 4, 5, 6. HIVAN is 
associated with marked increases in serum 
creatinine (SeCr) due to reduced creatinine 
clearance (CrCl), a surrogate marker of renal 
impairment during cART.  
The widespread use of cART before the immune 
system is severely depressed has reversed the 
incidence of HIVAN, and has resulted in resolution 
of renal function in affected patients 6. 
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Notwithstanding the benefits of cART, it is 
associated with adverse drug reactions, including 
renal impairment, occurring at various times and to 
different degrees 3, 6, 7. In a recent publication, we 
outlined the possible effects that tenofovir 
disoproxil fumarate (TDF) and ritonavir containing 
second-line cART may have had on the renal 
function of patients in this study 3.  
However, we lacked data on the renal function 
before cART initiation and renal function data for 
the larger period of first line cART, which limited 
our discussion. The current study benefited from 
the availability of data on CrCl at three period 
points: before cART initiation; during first line 
cART; and during second-line cART.   
Consequently, in this paper, we present our 
findings on CrCl over time per patient, and provide 
plausible explanations for the observations seen. In 
addition, discuss the implications for the future 
management of HIV patients in Namibia and wider. 
This is particularly important in Namibia with its 
high prevalence of HIV as well as high prevalence 
of HIV among women 8, similar to other Africa 
countries, but not to Western countries 9. This has 
important pharmacogenetic consequences. 
MATERIALS AND METHODS: This was a 
retrospective longitudinal study that adopted 
qualitative and quantitative methods of analysis. 
The study site was an HIV clinic, hosted in a 
leading hospital in Namibia, treating these patients. 
The study population were patients who were 
receiving second-line cART. To evaluate the 
SDWLHQWV¶UHQDO IXQFWLRQZHFDOFXODWHG&U&OE\WKH
Cockcroft-Gault (C-G) method 7 before and at 
various time points after initiation of first-line 
cART. The C-G method was used because it is the 
one recommended by the Ministry of Health and 
Social Services (MoHSS) in Namibia for assessing 
renal function in HIV infected patients 10.  
Renal function was considered to have declined if 
the last CrCl was less than the CrCl prior to cART 
LQLWLDWLRQ E\  7KH SDWLHQWV ZHUH SODFHG LQ
renal function categories based on their estimated 
&U&ODVIROORZVVWDJH,ZDVVWDJH,,ZDV± 
<90; stage III was 30 ± <60; stage IV was 15-<30 
and Stage V <15 ml/min 11.  
7KH GDWD VRXUFH ZDV WKH SDWLHQWV¶ FDUH ERRNOHWV
SPSS was used for statistical analysis. We used 
Chi-square test to compare renal function between 
JURXSV DQG 0F1HPDU¶V WHVW WR DVVHVV FKDQJHV LQ
renal function. Renal function was considered to 
have changed significantly if the magnitude of the 
FKDQJHZDVRU12.  
We set the confidence level at 95% and the 
statistical significance at a p-value of <0.05. The 
study received ethical approval from the Faculty of 
Health Sciences, University of Namibia, and from 
the MoHSS in Namibia. 
RESULTS: 
6XPPDU\RI3DWLHQWV¶&KDUDFWHULVWLFVA total of 
81 patients were initially included in the study; 
however, 10 were subsequently excluded because 
they had only one SeCr test performed making 71 
in all for analysis. The majority of the included 
patients were adults [76.1% (n = 54)] and female, 
[59.2% (n = 42)]. Table 1 documents the patient 
characteristics, immune status, cART regimens, 
period spent on cART, and other clinical data. 
CrCl before Initiation of cART: Prior to initiation 
of cART, 70.4% (n = 50) and 29.6% (n = 21) of 
patients had abnormal and normal CrCl, 
respectively. In the following sections, these are 
presented with regards to the state of CrCl the 
patient had before and during cART. 
CrCl during cART in Patients who had Normal 
CrCl Prior to cART: Patients who had normal 
CrCl were initiated on first-line cART regimens as 
follows: AZT-based regimens, n = 6; d4T - based 
regimens, n = 5; and TDF- based regimens, n = 10. 
At the time of data collection, 76.2% (n = 16) had 
changed from normal to abnormal CrCl status, 
leaving 23.8% (n = 5) with normal CrCl values.   
The abnormal CrCl was detected after 
approximately six months of cART for 37.5% (n = 
6) of the patients, while for the remaining 62.5% (n 
= 10) the decline was detected at widely variable 
time points, all of which were beyond one year of 
cART Table 2, Fig. 1. The mean (medium) time 
that had elapsed from cART initiation to the 
detection of renal impairment was 36.7 (17.7) 
months Table 3.   
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TABLE 1: PATIENT DATA SUMMARY 
Item All Female Male 
Number (%) of patients 71 (100) 42 (59.2) 29 (40.8) 
Paediatric Patients 17 (23.9) 9 (12.7) 8 (11.2) 
Adult Patients: No (%) 54 (76.1) 34 (47.9) 20 (28.2) 
Age    
Mean Age (years) Paediatric Patients (confidence limits) 12.4 (3.5 ± 8.9) 12 (7.9 ± 16.1) 12.7 (9.6 ± 15.7) 
Mean Age (years) Adult Patients (confidence limits) 36 (25.8 ± 46.2) 32.5 (23.6 ± 41.4) 42 (32.4 ± 51.6) 
Weight (kg)    
Mean weight before initiating cART (Paediatric) 39 (18 ± 60) - - 
Mean weight before initiating cART (Adults) 57 (45 ± 69) 56 (44 ± 57) 58 (47 ± 70) 
SeCr tests    
Mean no. of tests per patient (confidence limits) 3.8 (4.0 ± 6.0) 5 (3.8 ± 6.0) 5 (3.7 ± 6.5) 
Immune Status    
Adults    
Average CD4 count before initiating ART 171 (31 ± 303) 169 (23 ± 315) 171 (42 ± 296) 
Average CD4 count at switching 319 (61 ± 577) 262 (50 ± 473) 274 (3 ± 545) 
Paediatrics    
Average CD4 count before initiating ART 177 (65 ± 290) - - 
Average CD4 count at switching 488 (221 -754) - - 
cART    
First-line Regimen Received: No (%)    
AZT/3TC/EFV 3 (4.2) 1 (1.4) 2 (2.8) 
AZT/3TC/NVP 27 (38.0) 16 (22.5) 11 (15.5) 
AZT/ddI/LPV 1 (1.4) - 1 (1.4) 
D4T/3TC/NVP 15 (21.1) 9 (12.7) 6 (8.5) 
D4T/3TC/EFV 1 (1.4) - 1 (1.4) 
TDF/3TC/EFV 5 (7.0) 3 (4.2) 2 (2.8) 
TDF/3TC/NVP 17 (23.9) 11 (15.5) 6 (8.5) 
TDF/FTC/EFV 1 (1.4) 1 (1.4) - 
TDF/FTC/NVP 1 (1.4) 1 (1.4) - 
Second-line Regimen: No (%)    
TDF/3TC/AZT/LPV/r 71 (100) 42 (59.2) 29 (40.8) 
Period on ART(Years)    
First-line ART (n=71) 2.8 (0.6 ± 5.0) 2.7 (0.6 ± 4.8) 3.0 (0.7 ± 5.3) 
Second-line ART (n=47) 1.7 (0.4 ± 3.0) 1.8 (0.3 ± 3.3) 1.6 (0.7 ± 2.6) 
Chronic Disease [Number (%)]    
Peripheral Neuropathy 1 (1.4) 1 (1.4) - 
Anaemia 1 (1.4) 1 (1.4) - 
Syphylis 3 (4.2) 1 (1.4) 2 (2.8) 
Tuberculosis 3 (4.2) 1 (1.4) 2 (2.8) 
Hepatitis B 11 (15.4) 7 (9.9) 4 (4.6) 
Co-Medication    
Before initiating ART    
RHZE 3 (4.2)   
During ART No records   
TABLE 2: NUMBER OF PATIENTS AND TIME POINTS AT WHICH CHANGES FROM NORMAL TO 
ABNORMAL CrCl OCCURRED 
Renal function Before 
cART 
During cART 
(both first- and 
second-line 
regimen) 
Mean (confidence 
limits) period spent on 
cART (in Months) 
Number with abnormal renal function 
detected within this period (in Months) 
Totals (after 
initiation of 
cART) 0-6 7-12 13-18 19-24 >24 
No. with 
normal CrCl 
21 5* 43.9 (6.2 - 81.7) n/a n/a n/a n/a  5 
No. with 
abnormal CrCl 
0 16# 40.1 (3.8 - 76.4) 2 4 3 - 7 16 
*Of these, 2 were receiving TDF-containing cART during first-line; # of these, 7 received TDF during first line, and 6 during 
second line. 
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This abnormality in CrCl was detected during first-
line cART for 42.9% (n = 9) and during second- 
line cART for 33.3% (n = 7) of the patients. Of the 
9 patients, seven had received TDF-containing first 
line cART, while 2 (9.5%) had received AZT- and 
d4T- based cART regimens. Of the 7 patients on 
second-line cART, six (n = 6) were exposed to 
TDF only during second-line cART. Of the 23.8% 
who still had a normal CrCl at the time of data 
collection, three had received TDF-containing 
cART for 12.5, 14.5, and 60.4 months, and two had 
received AZT-based cART for 82.3 and 93.8 
months. 
CrCl during cART in Patients who had 
Abnormal CrCl Prior to cART: The patients who 
had abnormal renal function (n = 50) prior to 
initiation of cART received their initial cART 
regimens as follows: AZT-based regimens n = 25; 
d4T - based regimens, n = 11; and TDF-based 
regimens, n = 14). Twelve of the 50 (24.0%) 
patients experienced normalisation in CrCl Table 
4. 
TABLE 3: TIME (MONTHS) TAKEN FOR CHANGE IN 
CrCl TO BE OBSERVED 
 Mean 
(Months) 
Confidence 
Interval 
(Months) 
Median 
(Months) 
Time taken for 
Decline in CrCl to 
be observed 
36.7 -1.2 ± 74.7 17.7 
Time elapsed for 
Improvement in 
CrCl to be observed 
47.4 19.4 ± 75.3 33.7 
TABLE 4: CHANGES FROM ABNORMAL TO NORMAL CrCl: TIME POINTS AT WHICH CHANGES 
OCCURRED 
Renal function before 
cART 
During cART 
(both first- and 
second-line 
regimen) 
Mean (confidence 
limits) period spent 
on cART (in 
Months) 
Number with normal renal function 
detected within this period (in Months) 
Totals (after 
initiation of cART) 
0-6 7-12 13-18 19-24 >24 
No. with 
normal CrCl 
0 12 56.8 (27.8 ± 85.8) - - - - 12 12 
No. with 
abnormal CrCl 
50 38 43.1 (14.1 ± 72.1) n/a n/a n/a n/a n/a 38 
NB: Thirteen (n = 13) patients experienced increases in CrCl ranging from 12% to 23%. These were not counted amongst those 
with improved CrCl. 
Of the normalisations: 3(25%) and 9(75%) 
occurred during first- and second- line cART, 
respectively. Some patients experienced further 
decline in CrCl (n = 8), while for others no 
significant change in CrCl was observed (n = 30). 
The mean time that elapsed for improvement to be 
detected was 47.4 months, with a median of 33.7 
months Table 5. 
TABLE 5: PERIOD SPENT ON cART FOR PATIENTS 
:,7+$1'7+26(:,7+2-23% 
 
Mean 
(months) 
Confidence 
interval 
Median 
(months) 
Period on cART 
for patients with 
LQFUHDVHLQ
CrCl 
47.4 19.4 - 75.3 33.7 
Period on cART 
for patients with 
12-23% increase 
in CrCl 
31.2 -12.6 - 75.0 11.5 
Assessment of Factors Affecting the CrCl 
Outcome: Of the 21 patients who had a normal 
CrCl pre-cART initiation, the majority (n = 18) had 
a baseline CD4 count <200 cells/mm3. The baseline 
CD4 count did not influence CrCl (p-value = 0.09). 
Similarly, the age-group of the patients did not 
have an effect on the CrCl stage of the patient prior 
to initiation of cART, even though there were more 
adults by proportion with abnormal CrCl (Cl 95%, 
OR = 2.8 [0.9 ± 8.9]; p = 0.076). Normalisation in 
CrCl was significantly lower in adults than in 
paediatric patients: 7/41 (17.1%) and 5/9 (55.6%); 
p-value = 0.014 Table 6.  
TABLE 6: NUMBERS CHANGED FROM NORMAL TO 
ABNORMAL AND VICE-VERSA, AND TAKEN FOR ANY 
CHANGES TO BE OBSERVED 
 Adult 
patients 
Paediatric 
patients 
Significance 
(X2) 
Number changed from 
normal to abnormal 
7 (17.1%) 5(55.6%) p-value = 
0.014 
Number unchanged- 
or normalised 
34(82.9%) 4(44.4%) 
 
Time in months on 
ART for improvement 
in CrCl to be 
observed: mean 
(confidence limits) 
39.8 (24.0 
± 55.6) 
62.2 (26.2 
± 98.5)* 
 
*51.25 (20.9 - 81.6) for the paediatric patients after removal of the 
record of one patient who had spent 106.8 months on cART 
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Furthermore, experiencing normalisation in 
paediatric patients was six times greater than that in 
the adults: OR = 6.1. Normalisation of CrCl was 
observed to occur close to two years after cART 
initiation Fig. 1.   
 
FIG. 1: ADR (RENAL IMPAIRMENT) OBSERVED AT 
EARLIER TIMES THAN NORMALISATION OF CrCl 
DISCUSSION: Our findings present a global 
picture of the plausible renal function outcomes in 
HIV infected patients after initiation of cART, 
since the study participants existed in two groups: 
those with normal CrCl and others with abnormal 
CrCl before cART. As mentioned, the Acquired 
Immunodeficiency Syndrome (AIDS) in HIV-
infected patients may be accompanied by HIVAN 
13, 14
. This kidney disease is known to affect black 
patient populations more than others 4, 5. Whilst 
cases of HIVAN have been reported in 
asymptomatic patients, and at the level of 
seroconversion, HIVAN is still generally 
recognised as a complication of AIDS 15. As such, 
one of the risk factors for HIVAN is a low baseline 
CD4 count (<200 cells/mm3) 16. HIVAN is 
associated with a rapid decline in the glomerular 
filtration rate (GFR) coupled with moderate to 
nephrotic range proteinuria, which if untreated will 
progress to end stage renal disease (ESRD) and 
ultimately death 4. Even though the majority of 
patients on our study were black Africans, with a 
baseline CD4 count <200, the data did not show 
any association between the observed CD4 counts 
and the stage of CrCl (p = 0.09); consequently, 
appearing to rule out HIVAN as the cause of the 
low CrCl before the initiation cART.  
Moreover, for a number of the patients, the stage of 
abnormal CrCl was sustained without further 
decline, which is not expected to happen in patients 
with HIVAN since the characteristic feature of 
HIVAN is aggressive focal segmental glomerulo-
sclerosis accompanied with rapid decline in 
glomerular filtration 15. 
)XUWKHUPRUH LQGLYLGXDO SDWLHQW¶V DJHV FRXOG QRW
explain the differences in CrCl amongst the 
patients before initiation of cART. In addition, 
assessment of CrCl by age group - adults vs. 
paediatric - did not show any influence of age on 
CrCl. In regards to age or age-groups, our findings 
are similar to those by Chaisir et al., who studied 
the risk factors for renal impairment in patients 
receiving TDF - containing cART, but did not 
include increasing patient age as one of the risk 
factors for TDF - associated renal impairment 17. 
Against this in the study by Queseda et al., 
increasing age was listed amongst the risk factors 
18
. Overall, among the possible causes of renal 
impairment prior to cART initiation in our study, 
HIV infection was the known common factor. We 
observed two outcomes in patients who had normal 
CrCl before starting cART. The first was a 
significant drop in CrCl, associated with a change 
from normal to abnormal CrCl (n = 16, 76.2%); 
and the second was the maintenance of normal 
CrCl (n = 5, 23.8%). Antiretroviral drug-associated 
renal impairment is a known phenomenon. 
Amongst these medicines, TDF is associated with 
the highest incidence of renal impairment as it 
interferes with nephrogenic proximal tubular 
function. This might explain why the majority of 
patients in this category who experienced a 
significant decline in CrCl during first-line cART 
were receiving TDF - containing cART (n = 7; 
77.8%).  
Furthermore, of the patients who experienced a 
decline in CrCl during second-line cART, the 
majority (n = 6, 85.7%) only became exposed to 
TDF during second-line cART. As such, TDF is a 
probable cause of the decline in CrCl. However, as 
Queseda et al., and Chaisiri et al., discuss, the 
plausible synergy between TDF and ritonavir 
(RTV) as a risk factor for renal impairment cannot 
be overlooked 17, 18. At the time of data collection, 
all these patients were receiving TDF containing 
second line regimens, which means that they had 
not experienced TDF-associated acute renal 
impairment such as the Fanconi Syndrome. 
Overall, our data showed a slow decline in CrCl, 
which may be interpreted as one of the slow 
progressing drug-related renal diseases such as 
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arterio-nephrosclerosis 6. The abnormal CrCl that 
we observed prior to initiation of cART may have 
been evidence of HIV-associated renal impairment 
- not necessarily HIVAN, although there may have 
been other causes. Our suspicion of HIV associated 
renal impairment was augmented by the fact that 
we observed improvement in CrCl after initiation 
RI F$57$FFRUGLQJ WR WKH µLPSURYHPHQW¶ FULWHULD
we used, improvement was observed in 16.9% (n = 
12) of the patients; of whom, five were paediatric 
and seven were adults.   
Interestingly, the proportion of paediatric patients 
who experienced improvement in CrCl was 
significantly greater than that of adults (p = 0.014). 
In addition, we noted that the normalisation of CrCl 
in the paediatric patients occurred after long 
periods on cART compared to the normalisation we 
observed in the adult patients. This finding, albeit 
in a small sample size, appears to mean that HIV-
associated renal damage in paediatric / adolescent 
patients was greater in severity than seen in adults. 
Evaluation of the observed improvement against 
the time it occurred in the five paediatric patients 
favours this hypothesis. However, the number of 
paediatric patients is too small for inferences to be 
made. This will be the subject of future research. 
Furthermore, a number of paediatric patients 
remained in the abnormal state even after 
prolonged periods of cART. 
In another group of patients (n = 13), we observed 
sustained increases in CrCl of 12% to 23% above 
the baseline. Since these increases were sustained, 
it is possible that with continued cART, the CrCl of 
these patients will rise pURJUHVVLYHO\WRThis 
supposition is based on the fact that the average 
period spent on cART for the 12 patients who 
experienced an improvement in CrCl was generally 
longer than the period spent on cART by those who 
had increases in CrCl <25%: 27.4 (11.5 - 43.4) and 
17.3 (5.6 - 28.6) months, respectively.  Patel et al., 
found the recovery of renal function occurred 
rapidly 19. However, in our study, the time that 
elapsed before an improvement in CrCl was 
observed (50.5[33.7] months) was longer than the 
time taken for a decline (renal impairment) to take 
place (33.5[13.5] months). The shortest time for a 
decline to be observed in our patients was 3.9 
months, while the shortest time for an improvement 
to be observed was 23 months.  
Rapid improvement in CrCl would be observed in 
patients who had TDF-associated Fanconi 
syndrome, for whom TDF would be withdrawn. In 
some patients, who had an abnormal CrCl in the 
pre-cART initiation period there was neither 
improvement nor further decline in CrCl. We could 
not ascertain the cause or predictors of renal 
impairment in these patients. 
Limitations: The lack of information on the other 
possible aetiologies for renal impairment was a 
major confounder. However, the observed 
improvements in 12 patients indicate that HIV 
infection may have been the sole cause of renal 
impairment. In addition, the sustained increases in 
CrCl in 13 patients may rule out other possible 
causes of renal impairment, with the expectation 
that renal function in these patients will normalise. 
The fact that renal function is generally not 
monitored in patients receiving non-TDF-
containing regimens does not negate the possibility 
of development of renal insufficiency during first-
line cART. Nevertheless, the probability of renal 
impairment having occurred during first-line cART 
in these patients is low. In any case, renal 
impairment would not have been detected except if 
the clinical presentation of the patient warranted 
the assessment of renal function. Other possible 
causes of renal impairment cannot be ruled out. 
Because the cART records of HIV infected patients 
are stored separately from other medical records in 
health facilities in Namibia, we were unable to 
ascertain the cause of the abnormal CrCl in the pre-
cART initiation period. Another limitation was the 
low number of patients in the study. We will 
though be following this up with further patients. In 
addition, we only collected data from one hospital. 
However, this was a leading hospital clinic treating 
HIV patients in Namibia. Despite these limitations, 
we believe our findings are robust providing 
guidance for the future. 
CONCLUSION: It is likely HIV infection was 
responsible for renal impairment in those patients 
who experienced renal improvement after initiating 
cART. This is not a new finding. However, there 
was diversity in the rate of recovery from renal 
impairment in our patients. The slow recovery we 
observed in paediatric patients compared to the 
adult patients was an interesting finding which 
needs further investigation.  
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There is also a need to gather further information 
on co-morbidities in these patients, especially those 
that are known to affect renal function such as 
diabetes mellitus and hypertension, which can be 
facilitated by the integration of HIV with other 
services and data in resource limited settings. Renal 
biopsies would also be of great value. Pre-cART 
renal impairment in HIV infected patients does not 
always preclude the use of TDF-containing cART 
as improvement in renal function is possible. 
Consequently, this makes the prediction of the 
occurrence of renal pathology in a patient receiving 
TDF-containing cART extremely challenging. In 
view of this, co-administration of TDF with other 
nephrotoxic drugs should be undertaken with 
caution if unavoidable. Ultimately, it is critical that 
SDWLHQWV¶ UHQDO IXQFWLRQ LV PRQLWRUHG UHJXODUO\
during treatment. 
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